Canada

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Algernon Announces Enrollment of 50th Patient in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 02, 2020

Details:

The Company’s multinational Phase 2b/3 human trial for COVID-19 is entitled, "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease."

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 13, 2020

Details:

The Company’s multinational Phase 2b/3 human trial for COVID-19 is a randomized open label Phase 2b/3 study of the safety and efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease.

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 05, 2020

Details:

Algernon Pharmaceuticals has enrolled its first patient in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The countries participating in the study include the U.S., Australia, Romania and the Philippines.

Edesa Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study

Lead Product(s): EB05

Therapeutic Area: Infections and Infectious Diseases Product Name: EB05

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 30, 2020

Details:

EB05 is an experimental monoclonal antibody that the company believes could regulate the overactive immune response associated with Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients.

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 16, 2020

Details:

Algernon's multinational Phase 2b/3 human trial for COVID-19 is a randomized open label Phase 2b/3 study of the safety and efficacy of NP-120 (Ifenprodil) for the treatment of hospitalized patients with confirmed COVID-19 disease.

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Algernon Gets Ethics Approval for Lfenprodil’s Covid-19 Trial in US

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 25, 2020

Details:

The Company is advancing on its multinational Phase 2b/3 human trial for COVID-19 entitled, "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease.

Edesa Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study

Lead Product(s): EB05

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

Edesa Biotech has received expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, which the company is developing as a potential treatment for moderate to severe COVID-19 patients.

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Algernon Submits IND Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 25, 2020

Details:

Algernon has submitted an Investigational New Drug application with the USFDA for its planned multinational Phase 2b/3 study of its re-purposed drug NP-120 as a potential therapeutic treatment for patients with COVID-19. Ifenprodil is an NMDA receptor antagonist.

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Algernon Seeks Ethics Approval for Covid-19 Trials in Australia

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

Ifenprodil, an NDMA glutamate receptor antagonist exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. Upon receiving all ethics approvals, the trial will begin as a Phase IIb study comprising 100 patients.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Algernon Pharmaceuticals

Algernon Announces Enrollment of 50th Patient in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Algernon Pharmaceuticals

Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Algernon Pharmaceuticals

Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Edesa Biotech

Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study

Algernon Pharmaceuticals

Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19

Algernon Pharmaceuticals

Algernon Gets Ethics Approval for Lfenprodil’s Covid-19 Trial in US

Edesa Biotech

Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study

Algernon Pharmaceuticals

Algernon Submits IND Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19

Algernon Pharmaceuticals

Algernon Seeks Ethics Approval for Covid-19 Trials in Australia